Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN-90806 in Proliferative Diabetic Retinopathy
NCT02475109Phase 1Completed
- Sponsor
- PanOptica
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PAN-90806 in proliferative diabetic retinopathy (PDR), sponsored by PanOptica. Primary endpoint: Number of Patients with Adverse Events at 2 months. Started Aug 2015; status: completed.
02
Drugs
PAN-90806
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02475109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475109.